Zobrazeno 1 - 10
of 1 442
pro vyhledávání: '"Noboru YAMAMOTO"'
Autor:
Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of
Externí odkaz:
https://doaj.org/article/7dbdc5c5725f466f9c680a126d352047
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundDrug-induced lung disease (DILD) is a considerable and potentially fatal adverse event with poorly understood risk factors. Large-scale, data-driven analyses investigating regional discrepancies in DILD incidence are lacking. The aim of thi
Externí odkaz:
https://doaj.org/article/c7de1f21921d430fa548fa71b4c56341
Autor:
Konstantin Penkov, Igor Bondarenko, Daria Viktorovna Saenko, Yaroslav Kulyaba, Jun Guo, Yi Gong, Noboru Yamamoto, Yevhen Stepanovych Hotko, Vasyl Boyko, Natalya Vladimirovna Fadeeva, Grygorii Mykolaiovych Ursol, Hee Kyung Ahn, Nikolay Viktorovich Kislov, Chia-I Shen, Craig Davis, Karey Kowalski, Elisabete Michelon, Dmitri Pavlov, Tomoko Hirohashi, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Sasanlimab (PF-06801591), a humanized immunoglobulin G4 monoclonal antibody, binds to programmed cell death protein-1 (PD-1), preventing ligand (PD-L1) interaction. Objectives: To evaluate pharmacokinetics (PK), safety, tolerability, and
Externí odkaz:
https://doaj.org/article/a3ad25bc9da747acad6405e92fd609c8
Autor:
Shinji Kohsaka, Shigehiro Yagishita, Yukina Shirai, Yusuke Matsuno, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Masachika Ikegami, Rina Kitada, Ken-ichi Yoshioka, Kohta Toshimitsu, Kimiyo Tabata, Akira Yokoi, Toshihiko Doi, Noboru Yamamoto, Takashi Owa, Akinobu Hamada, Hiroyuki Mano
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract E7820 and Indisulam (E7070) are sulfonamide molecular glues that modulate RNA splicing by degrading the splicing factor RBM39 via ternary complex formation with the E3 ligase adaptor DCAF15. To identify biomarkers of the antitumor efficacy o
Externí odkaz:
https://doaj.org/article/86ebc4f788534403a85a1a26be337bd6
Autor:
Yasutoshi Kuboki, Masafumi Ikeda, Shigehisa Kitano, Takafumi Koyama, Noboru Yamamoto, Yuki Yamaguchi, Yuki Nakagawa, Takaaki Ishida, Hidenori Mizugaki, Takatsugu Narikiyo, Ryoko Takubo, Chika Ogami, Mayuko Sekiya
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to immunosuppress
Externí odkaz:
https://doaj.org/article/3d04b9ef93094c8580ba143d1ba1c0ee
Autor:
Teruhiko Yoshida, Yasushi Yatabe, Ken Kato, Genichiro Ishii, Akinobu Hamada, Hiroyuki Mano, Kuniko Sunami, Noboru Yamamoto, Takashi Kohno
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 1, Pp 29-44 (2024)
The journey to implement cancer genomic medicine (CGM) in oncology practice began in the 1980s, which is considered the dawn of genetic and genomic cancer research. At the time, a variety of activating oncogenic alterations and their functional signi
Externí odkaz:
https://doaj.org/article/098513c931e64fbb831a95e5cc3e139e
Autor:
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Retifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese pat
Externí odkaz:
https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd
Autor:
Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, Satoshi Nishiwaki, Shota Tanaka, Eishi Baba, Masashi Kanai, Ichiro Kinoshita, Hidekazu Shirota, Hideyuki Hayashi, Naohiro Nishida, Toshio Kubo, Nobuaki Mamesaya, Yayoi Ando, Natsuko Okita, Taro Shibata, Kenichi Nakamura, Noboru Yamamoto
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102447- (2024)
Summary: Background: BRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidat
Externí odkaz:
https://doaj.org/article/e4b60dfa03624d70ba3fcc3329c90c50
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/df6bf30b5b044e459a1c6362158a803a
Autor:
Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2909-2923 (2023)
Abstract Background Risk factors for predicting pneumonitis during durvalumab consolidation after chemoradiotherapy (CRT) in locally advanced non‐small cell lung cancer (LA‐NSCLC) are still lacking. Extracellular vesicles (EVs) play a crucial rol
Externí odkaz:
https://doaj.org/article/c26bd9ec8eaf4da5b06f23bbc99b43dc